India, May 5 -- Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis or UC.
The company noted that TREMFYA is positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks.
Johnson & Johnson said the data at Week 24 show patients treated with TREMFYA 400 mg SC induction followed by SC maintenance dose regimens of either 100 mg every eight weeks or 200 mg every four weeks demonstrated statistically significant and clinically meaningful improvements across all clinical and e...